EP1257666A1 - Methode zum nachweis mycobacterium tuberculosis spezifischer inteine und deren verwendung für tuberkulose - Google Patents
Methode zum nachweis mycobacterium tuberculosis spezifischer inteine und deren verwendung für tuberkuloseInfo
- Publication number
- EP1257666A1 EP1257666A1 EP01907833A EP01907833A EP1257666A1 EP 1257666 A1 EP1257666 A1 EP 1257666A1 EP 01907833 A EP01907833 A EP 01907833A EP 01907833 A EP01907833 A EP 01907833A EP 1257666 A1 EP1257666 A1 EP 1257666A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- intein
- specific
- site
- tuberculosis
- mycobacterium tuberculosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000017730 intein-mediated protein splicing Effects 0.000 title claims abstract description 185
- 238000000034 method Methods 0.000 title claims abstract description 76
- 241000187479 Mycobacterium tuberculosis Species 0.000 title claims abstract description 66
- 201000008827 tuberculosis Diseases 0.000 title claims description 63
- 238000003745 diagnosis Methods 0.000 title description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 238000013519 translation Methods 0.000 claims description 50
- 239000000523 sample Substances 0.000 claims description 43
- 238000001514 detection method Methods 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 101150079601 recA gene Proteins 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 25
- 230000003321 amplification Effects 0.000 claims description 24
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 24
- 238000013518 transcription Methods 0.000 claims description 24
- 230000035897 transcription Effects 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 22
- 230000004807 localization Effects 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 18
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 14
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 14
- 108010042407 Endonucleases Proteins 0.000 claims description 14
- 102000004533 Endonucleases Human genes 0.000 claims description 14
- 108020004705 Codon Proteins 0.000 claims description 13
- 238000011002 quantification Methods 0.000 claims description 11
- 108010055016 Rec A Recombinases Proteins 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 230000016434 protein splicing Effects 0.000 claims description 10
- 102000001218 Rec A Recombinases Human genes 0.000 claims description 9
- 101150076598 dnaB gene Proteins 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 238000011990 functional testing Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 102000006495 integrins Human genes 0.000 claims description 7
- 108010044426 integrins Proteins 0.000 claims description 7
- 108090000364 Ligases Proteins 0.000 claims description 6
- 102000003960 Ligases Human genes 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 5
- -1 nucleotide triphosphates Chemical class 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000001226 triphosphate Substances 0.000 claims description 4
- 235000011178 triphosphate Nutrition 0.000 claims description 4
- 239000000284 extract Substances 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000758 substrate Substances 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 241000186359 Mycobacterium Species 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010006519 Molecular Chaperones Proteins 0.000 description 4
- 241000187472 Mycobacterium chitae Species 0.000 description 4
- 241000187471 Mycobacterium fallax Species 0.000 description 4
- 241000187485 Mycobacterium gastri Species 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 238000011895 specific detection Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000187477 Mycobacterium thermoresistibile Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 108010029942 microperoxidase Proteins 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001147832 Mycobacterium shimoidei Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187486 Mycobacterium flavescens Species 0.000 description 1
- 241000187470 Mycobacterium gadium Species 0.000 description 1
- 241000114916 Myxidium gadi Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Definitions
- the present invention relates to the detection of
- Mycobac teri um tubercul osi s for the diagnosis of tuberculosis in a patient.
- the detection method of the invention is based on the research in a biological sample of a patient of an intein specific for Mycobacteri um tubercul osis.
- the invention also relates to a kit for implementing said method.
- Mycobacteri um tubercul osi s is a strict human pathogen also capable of infecting some animal species living alongside it. It is the agent responsible for human tuberculosis. Infection, mainly by air, most often manifests as a lung infection.
- Tuberculosis is one of the most fatal infections, and it has been reported that the number of deaths increases each year by 10% (Bloom and Murray, Science (1992), 257, 1055-64). Tuberculosis is a public health problem because not only is a large number of children in developing countries already infected or will be infected before reaching adulthood, but tuberculosis is also one of the opportunistic infections developed by immunocompromised patients such as AIDS patients. In addition, many strains of Mycobacterium tuberculosis show resistance to various antibiotics (Shankar et al., Lancet (1990), 335, 423-42), which makes treatment all the more difficult.
- Mycobacteri um tuberculosis corresponding for example to the 16S rRNA subunit have been widely described for detecting tuberculosis infections.
- the object of the present invention is precisely to offer new means of rapid, sensitive and specific diagnosis of an infection by Mycobacterium tuberculosis. This object is achieved according to the invention thanks to the detection of one or more specific inteins of Mycobacterium tuberculosis.
- inteins are protein introns which are integrated into proteins. The protein splicing of these introns is necessary for the survival of the organism to which they belong. Thus inteins have been described in Mycobacterium tuberculosis in the proteins RecA, Ppsl and DnaB.
- US Patent No. 5,795,731 reports a method of screening for antibiotics or antifungals capable of inhibiting protein splicing of the RecA intein from Mycobacteri um tubercul osis, but this document does not relate to a diagnostic method.
- this antibiotic screening method involves the prior cloning of the RecA intein into a reporter gene. It is a relatively cumbersome method to implement which also requires a cell culture step.
- inteins of Myc oba c t eri um tubercul osis are more particularly inteins capable of being present in several types of mycobacteria but whose localization is specific to Mycobacterium tuberculosis.
- the work carried out within the framework of the present invention has made it possible to identify several inteins whose localization is specific for Mycobacteri um tubercul osis. These are, for example, inteins localized at: - the ppsl site (b) of the nucleotide sequence coding for Ppsl (accession no. 2791395),
- the RecA intein from Mycobacterium tuberculosis is localized at the recA site (a) while the RecA inteins from Mycobacterium leprea, M. chitae, M. fallax, M. flavescens, M. gastri, M. thermoresistibile, M. shimoidei, when present, are located at the recA (b) site as shown in Table 1 below.
- the sequence of the recA gene of Mycobacterium tuberculosis without intein is represented in the sequence list in the appendix under SEQ ID No. 1, and the sequence of the corresponding protein is represented in the sequence list in the appendix under SEQ ID No. 2
- This sequence includes without the intein gene 1053 nucleotides.
- the recA site (a) at which the intein of the MyAcobacterium tuberculosis recA gene is inserted is located between the nucleotides at positions 753 and 754.
- the gene sequence of the intein of the recA gene of Mycobacterium tuberculosis comprises 1320 nucleotides and is represented in the sequence list in the appendix under the number SEQ ID No.
- sequence of the recA gene of Mycobacterium tuberculosis comprising the gene for the intein is represented in the sequence list in the appendix under SEQ ID No. 5 and the sequence of the corresponding protein is represented in the sequence list in the appendix under SEQ ID No. 6. This sequence comprises 2373 nucleotides.
- the recA (a) integrin of Mycobacterium tuberculosis appears to be a multifunctional protein, which is not only capable of protein splicing (Davis et al., Cell (1992), 71, 201-10; Kenneth et al., PNAS (1998), 95, 3543-8), but which also has protein ligase activity.
- Another specific Mycobacterium tuberculosis intein is located in the ppsl gene (Table 2).
- the intein of the ppsl gene of Mycobacterium tubercul osi s is localized at the ppsl (b) site, while the inteins of the pp sl gene of Mycobacteri um l eprea and gas tri are localized respectively at ppsl (a) and ppsl (c).
- the sequence of the pps l gene of Mycobac t eri um tuberculosis without intein is shown in the list of sequences in the appendix under SEQ ID No. 7 and the sequence of the corresponding protein is shown in the list of sequences in the appendix under SEQ ID No. 8.
- the sequence of the ppsl gene of Mycobacterium tuberculosis comprises, without the gene for intein, 1464 nucleotides.
- the ppsl (b) site at which the specific intein is inserted is located between the nucleotides at positions 756 and 757.
- the sequence of the intein gene, Mtu Ppsl comprises 1077 nucleotides and is represented in the list of sequences in annex under the number SEQ ID No. 9 and the sequence of the corresponding protein is represented in the sequence list in the annex under the SEQ ID No. 10.
- the sequence of the ppsl gene of Mycobacterium tuberculosis comprising the gene for the intein is represented in the annexed sequence list under SEQ ID No. 11 and the sequence of the corresponding protein is represented in the annexed sequence list under SEQ ID No. 12.
- the gene sequence comprises 2541 nucleotides.
- the integrin localized in ppsl (b) is a multifunctional protein, which is not only capable of protein splicing and therefore of a protein ligase activity and which also has specific endonuclease activity.
- the Ppsl integrin of Mycobacterium tuberculosis specifically cleaves the DNA sequence overlapping its site of insertion into the ppsl gene (site with a length ⁇ to 40 bp) of the nucleotide sequence represented in the sequence list in the appendix under the number SEQ ID No.
- DnaB also has a specific intein localized specifically in Mycobacterium tuberculosis.
- the DnaB intein from Mycoba ct eri um tubercul osi s is localized at the DnaB site (a) (Table 3), while the DnaB inteins from Mycobacterium leprea and M. avium are localized at DnaB (b) .
- the sequence of the dnaB gene of Mycobac t eri um tuberculosis without intein is shown in the list of sequences in the appendix under SEQ ID No. 13 and the sequence of the corresponding protein is shown in the list of sequences in the appendix under SEQ ID N ° 14.
- the sequence of the dnaB gene of Mycobacterium tuberculosis includes without the gene for intein 1377 nucleotides.
- the dnaB site (a) at which the specific intein is inserted is located between the nucleotides at positions 1197 and 1198.
- the Mtu dnaB integrin gene sequence comprises 1248 nucleotides and is represented in the sequence list in the appendix.
- sequence of the corresponding protein being represented in the sequence list in the appendix under the number SEQ ID No. 15.
- the sequence of the dnaB gene of Mycobac teri um tubercul osis comprising the intein gene is represented in the sequence list in the appendix under SEQ ID No. 17. This sequence comprises 2625 nucleotides.
- sequence of the corresponding protein is represented in the sequence list in the appendix under the number SEQ ID No. 18.
- the intein located in DnaB (a) seems to be a multifunctional protein.
- the research carried out in the context of the present invention has therefore enabled the inventors to design a rapid, specific and sensitive diagnostic method for Mycobacterium tuberculosis based on the specific localization of Mycoba c t eri um tuberculosis inteins.
- the subject of the invention is therefore a method for detecting and / or quantifying Mycobacterium tuberculosis in a sample, characterized in that the presence of an intein inserted at a site whose detection is detected in said sample localization is specific for Mycobacterium tuberculosis using a reagent which is specific for said localization, and possibly in that the detected signal is quantified.
- intein By the method of the invention is meant by intein, both the detection of an intein and of several inteins simultaneously or successively.
- the detection of the presence of a localized intein at a site which is specific for Mycobacterium tuberculosis can be carried out by any biological technique known to those skilled in the art, including or not comparison with controls.
- the invention more particularly contemplates hybridization techniques with labeled probes capable of specifically hybridizing with all or part of the gene coding for an intein if the latter is inserted at a site whose localization is specific for Mycobacterium tuberculosis.
- Such probes can be prepared from the sequences of the gene sites where the sequences coding for the inteins in Mycobacterium tuberculosis are inserted. They are preferably labeled probes capable of hybridizing specifically with: part of the sequence coding for the intein, and
- the presence of the recA gene intein is sought at the recA (a) site of Mycobacterium tuberculosis by the hybridization with a labeled probe capable of hybridizing specifically with part of the sequence coding for the recA intein and a region flanking the recA site (a) where said intein is inserted and the localization of which is specific for Mycobacterium tuberculosis.
- sequences in particular specific primers, regions flanking the insertion site of the specific intein of Myc oba cte ri um tuberculosis.
- techniques amplification we can cite for example PCR, NASBA, rolling circle etc ...
- This form of implementation using the diagnosis by amplification of specific inteins of Mycobacteri um tuberculosis has the advantage of being able to control the result. Indeed, a specific function of the intein whose corresponding gene has been amplified can be tested. This function can correspond for example to the endonuclease activity.
- the specific primers described previously for detection by amplification techniques will be chosen so as to subsequently allow expression in vivo or in vitro of said intein in order to be able to test its specific activity which may correspond to its endonuclease activity.
- the detection of an intein whose localization is specific for Mycobac teri um tubercul osi s allows conclusion and diagnosis of Mycobacterium tuberculosis infection.
- inteins As there are several sites for specific insertion of inteins into the genome of Mycobacterium tuberculosis, the detection of at least two of these specific inteins simultaneously makes it possible to increase the specificity of detection.
- at least three inteins localized specifically in the genome of Mycobacteri um tuberculosis are detected simultaneously.
- a preferred form of implementation of the method of diagnosis of Mycobacterium tuberculosis according to the present invention consists in expressing in vi tro the intein inserted at a site whose localization is specific for Mycobacteri um tubercul osi s, then at the detect and / or quantify it using a specific functional test of the activity of said intein expressed in vi tro.
- Ppsl of Mycobacteri um tubercul osis we express in vi tro, from the nucleic acids contained in the sample, the ppsl intein of Mycobacterium tuberculosis if it is present at the ppsl (b) site, then it is detected and / or quantifies it using a specific functional test of the activity of said intein expressed in vi tro.
- the functional test implemented in the method of the invention may be based in particular on: - the endonuclease activity of the specific intein of Mycobacterium tuberculosis; the protein ligase activity of the M. tuberculosis-specific intein;
- the subject of the invention is therefore very particularly a method for detecting and / or quantifying Myc oba ct eri um t uberc ulosis in a sample, characterized in that it comprises the following steps: a) the preparation, from said sample, of nucleic acid molecules comprising a polynucleotide sequence coding at least for an intein inserted at a site whose localization is specific for Mycobacteri um tubercul osis and the control elements necessary for the transcription and in vi tro translation of said intein; b) transcription and in vitro translation of the nucleic acid molecules prepared in step (a); c) detecting and / or measuring a specific intein function expressed in step (b).
- the sample from which the method of the invention is made can be any biological sample capable of containing Myc oba c t e r i um tuberculosis. It can of course be a raw biological sample such as blood, tissue or a body fluid such as sputum, saliva and sputum. These samples can also correspond to products of any DNA or RNA amplification methods or any nucleic acid products resulting from treatment commonly used in the field of biology.
- Mycobacterium is understood to mean both the microorganism Mycobacterium tuberculosis li itself and its genetic information.
- function also means any property of the specific intein, such as an enzymatic activity specific to the intein of Mycobac teri um tuberculosis. As indicated previously, this function can correspond by example to the endonuclease activity of the intein or to the protein ligase activity or to its protein splicing capacity.
- the detection and / or quantification method according to the invention is carried out in the presence of one or more substances capable of modifying the activity of the intein.
- the method of the invention also offers the advantage of being very sensitive. This sensitivity is explained by the multiplying coefficient of steps (b) and (c) corresponding respectively to the transcription, to the translation of the gene or genes prepared in step (a), coding for the intein, then to the detection. and / or measuring the function corresponding to the protein or proteins produced in step (b).
- the method of the invention can pass after the transcription step by a step of amplifying the transcripts by any technique known to those skilled in the art such as NASBA (nucleic Acid Sequence-based Amplification ), or TMA (Transcription Mediated Amplification) before the translation stage.
- the method of the invention is furthermore rapid and reproducible, since all the reactions are carried out in vitro within a few hours.
- the method of the invention not only makes it possible to demonstrate the presence and / or quantify a specific intein of Mycobacterium tuberculosis and therefore to carry out a specific diagnosis of Myc oba ct eri um tubercul osis, but it also makes it possible to characterize said intein . For example, by characterization, defining the spectrum of inhibition of specific intein by specific inhibitors or defining a pH range in which the intein is active. This particular mode of implementing the process of the invention makes it possible to define new antibiotics or substances capable of inhibiting functions of the specific intein and more particularly the protein splicing necessary for the survival of the organism to which it belongs.
- monitoring of an infection with M. tuberculosis can be implemented so as to periodically detect and / or quantify d '' a specific function of the intein in an organism having followed or not treatment with an antibacterial.
- the comparison of the results obtained at different times and their interpretation allows monitoring over time of the evolution of the infection. This type of monitoring allows the practitioner to understand the development of an M infection. tuberculosis. Interpreting the results then offers considerable decision support.
- the invention is more particularly interested in inteins located at:
- intein will also be understood to mean an intein inserted at a site whose localization is specific for Mycobacterium tuberculosis.
- Step (a) of sample preparation When the method of the invention consists in detecting Mycobacterium tuberculosis, a nucleic acid molecule coding for a specific intein is prepared in step (a) so as to be able to express it subsequently in vi tro.
- an amount of nucleic acid molecules is prepared in step (a) proportional to the amount of mycobacteria possibly present in 1 ′ sample.
- the preparation of the sample in step (a) of the method of the invention consists in placing a nucleic acid sequence coding at least for the intein inserted at a site whose localization is specific for Mycobac teri um tubercul osi s under the control of elements necessary for the transcription and in vi tro translation of said gene.
- control sequences of the polynucleotide coding for the specific intein according to the method of the invention are for transcription:
- RNA polymerase promoter optionally a 3' RNA polymerase terminator, and for translation: - a ribosome binding site
- RNA polymerase a translation stop codon followed by a few nucleotides, for example from 5 to 10 nucleotides.
- the promoter (in 5 ') and the terminator (in 3') if it is present, of an RNA polymerase are for example those of the RNA polymerase of phages T7, SP6, Q ⁇ or ⁇ .
- step (a) of the method of the invention consists in preparing the nucleic acid molecule by an amplification reaction of the gene coding for the specific intein, from the nucleic acids. of the sample. It can be an amplification by PCR or by techniques derived from PCR such as for example nested PCR or techniques different from PCR of the NASBA or SDA type or others.
- this preparation uses at least two oligonucleotides or at least two primers, two of which are located respectively at the terminals of the nucleotide sequence coding for the intein inserted at the level of a site whose location is specific to Mycobacteri um tuberculosis.
- primers which can correspond for example:
- RNA polymerase promoter for the sense primer or primers, at least the following elements corresponding to an RNA polymerase promoter, a ribosome binding site, a codon initiating translation in phase with the first codon of the intein gene and the sequence hybridizing at least 5 ′ to the polynucleotide coding for the specific intein, and
- the antisense primer (s) containing at least the following elements comprising the sequence hybridizing at least 3 'to the polynucleotide coding for the specific intein, a translation stop codon followed by a few nucleotides such as for example 5 to 10 and optionally an RNA polymerase terminator.
- the preparation of the nucleic acid molecule of step (a) can be carried out by any other method known to those skilled in the art, such as a restriction cut-off allowing the specific intein of interest to be recovered, followed by ligation. oriented with the control elements necessary for transcription and in vitro translation indicated above.
- these two primers are capable of hybridizing respectively at the terminals of the coding sequence for an inserted intein at a site whose location is specific for Mycobacterium tuberculosis.
- the portions of the primers which hybridize at least to the gene coding for a specific intein have a length of 7 to 150 nt in length, advantageously a length of 7 to 50 and preferably between 10 and 25 nt.
- these primers have a segment of at least 7 contiguous bases which are at least 70% complementary to a target sequence of 7 contiguous nucleotides located on either side of the polynucleotide coding for at least the specific intein of Mycobacterium tuberculosis.
- step (a) of preparation of nucleic acid molecules different forms of implementation of the method of the invention can be carried out. It is possible to combine in a single tube or not at least two detection and / or quantification reactions. One of the detection and / or quantification reactions concerns
- Mycobacterium tuberculosis Mycobacterium tuberculosis.
- the other so-called associated detection and / or quantification reaction concerns an organism or a process which it is useful to detect in parallel with
- Mycobacterium tuberculosis This parallel detection also involves the associated function of an organism or process, expressed in vi tro. This organism can also correspond to a mycobacterium.
- step b) can be simultaneous, which means that the translation phase is carried out simultaneously with the transcription, or broken down into two distinct stages of transcription and translation.
- Decoupling allows the use of different translation extracts depending on the origin of the screened DNA.
- the translation phase of the transcript is advantageously carried out with a translation extract of mycobacterial origin or of an origin close to that of the biological sample on which the method of the invention is practiced.
- the adequacy between the origin of the translation signals of the transcripts and the cell extract is optimized for optimal translation efficiency.
- These extracts are chosen for their ability to translate the transcripts.
- the method of the invention is remarkable in that it implements an adequacy between the punctuation of expression of the transcripts and the translation extracts used.
- These translation extracts are also characterized in that either they do not contain the property sought, or they contain it but that it is not detectable under the test conditions carried out to detect the function sought.
- a particular implementation of the method of the invention consists in using in step (b) a translation extract prepared from a modified bacterial strain.
- This extract can also correspond to a mixture of several translation extracts prepared from bacterial strains modified or not. It may, for example, be an E. coli translation extract overexpressing a chaperone A protein mixed with an E translation translation extract. coli overexpressing a chaperone B protein. Any type of mixture is possible as long as it corresponds to the characteristics described above.
- step (b) with a translation extract can also be carried out with a standard translation extract whatever the origin of the sample, for example an extract of E. coli and / or all (s) ) other cell extract (s) whether or not supplemented with interesting molecules such as those, for example, indicated above (tRNA, chaperone ). It is also possible to add to the translation extract of step (b) one or more substances promoting a more efficient folding or maturation of the expressed proteins, such as, for example, chaperones, detergents, tallow obetains, membrane extracts, etc.
- step (c) The functional test of step (c).
- specific substrates can be considered by those skilled in the art to demonstrate the presence of a specific intein function which may correspond, for example, to the protein ligase, endonuclease and protein splicing functions.
- Those skilled in the art may for example refer to works such as Methods In Enzymology or Annual Review Of Biochemistry, in which a large number of methods for assaying the activity of proteins and for preparing substrates have been described.
- the neosynthesized intein may specifically cleave a polynucleotide, of which the cut will be responsible for a fluorescence emission.
- the protein splicing function can be demonstrated by using, for example during the preparation of the sample by amplification in step (a), the following primers composed for: the sense primer, of an RNA polymerase promoter, of a ribosome binding site, of a part of a reporter gene such as that coding for microperoxidase (Spee et al., (1996) Eur. J. Biochem 241, 215-220 and Hirayama et al.
- the antisense primer of the sequence hybridizing 3 'to the polynucleotide sequence coding for a specific intein, or downstream of the polynucleotide sequence coding for a specific intein or on the polynucleotide sequence coding for a specific intein and on a sequence downstream of the polynucleotide sequence coding for a specific intein, of the other part of the reporter gene for microperoxidase, of a translation stop codon, and optionally of an RNA polymerase terminator.
- the specific intein can then be excised from the neosynthesized protein in step (b) to release the microperoxidase easily detectable by a functional test in step (c).
- the functional test in step (c) may or may not be direct.
- the measurement of the specific intein function expressed in step (b), if necessary, can be read directly in a fluorimetry reader if the measurement of the function uses a substrate corresponding to a fluorophore or colorimetry if the measurement of the function uses a chromophore.
- a fluorimetry reader if the measurement of the function uses a substrate corresponding to a fluorophore or colorimetry if the measurement of the function uses a chromophore.
- Quantification of Mycobacterium tuberculosis according to the invention.
- the invention also relates to a method for quantifying the function corresponding to a specific intein, from the nucleic acids present in said sample, characterized in that it comprises:
- step (c) consisting in measuring the function of the specific intein, then d) comparing the measurement of the function of the specific intein possibly present in the sample carried out in step (c) with a standard value or a set of standard values of said function measured on one or more standard samples according to a measurement method identical or equivalent to that of step 1 (c).
- a standard sample for carrying out step (d) above can be any sample containing:
- step (c) a quantity, advantageously known, of the gene or genes coding for the specific intein which can be transcribed and translated, and which will then be subjected to a transcription and translation treatment as in step (b), then the function of said intein will be measured according to a measurement method identical or equivalent to that of step (c);
- step (c) a quantity, advantageously known, of the specific intein, which will be measured according to a measurement method identical or equivalent to that of step (c); a quantity, advantageously known, of Mycobacterium tuberculosis, which will be measured according to a measurement method identical or equivalent to that of steps (a) (b) and (c).
- the standard sample can come from an identical or different medium from that on which steps (a) to (c) of the method of the invention are carried out. It can be the same medium but taken at a different time.
- Detection and / or quantification can be evaluated in particular with respect to a predetermined threshold or with respect to a standard curve allowing the comparison of the measurements of the specific intein function with those of standard samples.
- the steps of the method of the invention can be carried out successively without interruption by the same operator, advantageously on an automated device integrating each of the steps, or can be carried out discontinuously, possibly by different operators.
- the method of the invention can be advantageously automated if the number of samples to be analyzed is high.
- the nucleic acid samples are then placed on a support which can correspond, for example, to a chip or a titration plate containing several tens to several thousand locations. These supports are designed to allow:
- step a the preparation of the target sequences (step a), - the initiation of the transcription and translation reactions of the specific intein (step b) and the revelation of said intein (step c).
- the invention relates to a device comprising an arrangement of one or more supports, robots and a reader of said supports for carrying out the steps of the method described above.
- the invention therefore also relates to a kit for implementing a method of detection and / or quantification of Mycobac t eri um tubercul osi s described above.
- Said kit comprises in a first embodiment: the means for revealing a function of a specific intein, an RNA polymerase, nucleotide sequences allowing the preparation of the nucleic acid molecules (step a) coding at least for the 'intein, the four nucleotide triphosphates, the mixtures necessary for said preparation, for transcription and translation, possibly controls and what to make the standards.
- a kit according to the invention comprises:
- kits contain at least one labeled probe capable of specifically hybridizing with all or part of the gene coding for an intein if the latter is inserted at a site whose location is specific for Mycobacterium tuberculosis.
- probes can be prepared from the sequences of the gene sites where the sequences coding for the inteins in Mycobacterium tuberculosis are inserted.
- labeled probes are advantageously capable of hybridizing specifically with a part of the sequence coding for the intein, and a region flanking the site where said intein is inserted and whose location is specific to Mycoba ct eri um tuberculosis.
- kits for implementing a method for detecting the presence of a localized intein at a site which is specific for Mycobacterium tuberculosis using amplification techniques contain at least one pair of primers specific for the regions flanking the insertion site of the specific integrin of Mycobacteri um tubercul osis.
- Kits and supports can be considered for detection and / or quantification in addition to M. tuberculosis of one or more other functions associated with one or more other organisms or with one or more processes.
- the description which follows relates to examples of implementations of the invention relating to (i) the specific detection of Mycobacteri um tuberculosis by PCR, and (ii) the specific detection of M. tuberculosis by the function of the intein inserted into the recA site (a) of the RecA protein gene.
- Example 1 Specific detection of Mycobacterium tuberculosis by PCR.
- strains M. chi tae, M. fallax, M. gastri, M. thermoresistible, M. shimoideii were scraped on solid Lôweinstein-Jensen medium and are resuspended in 1 ml of sterile TE buffer (Tris-HCl 10 mM pH 8, EDTA 1 mM). 1 g of 0.1 mm diameter glass ball (BioBlock) is added and the mixture is vortexed for 2 min. for break the mycobacteria. Proteinase K (Sigma) is added to a concentration of 50 ⁇ g / ml final and the mycobacterial suspensions are incubated for 10 min. at 65 ° C and then for 10 min.
- the primers for the PCR amplification reaction were designed so as to be able to hybridize on either side of the recA (a) site in areas conserved for the mycobacterial species. These primers correspond to RecA-3 '(5' AGGATGTCGAACTCGGCCAGCTTGAA 3 ') and to R (a) (5'GCGTCGGTGCGCATGGACGTGCG 3') and are capable of hybridizing to positions 765-791 and 658-681 respectively of the recA gene of Mycobacterium tuberculosis.
- Amplification reactions by PCR are carried out using:
- An amplification product of 133 bp is observed in the cases where the matrix corresponds to M. chi tae, M. fallax, M. gastri, M. thermoresistibile, M. shimoide and M. leprea.
- an amplification product of 1453 bp is observed if the matrix corresponds to M. tuberculosis. Only the matrix corresponding to M. tuberculosis makes it possible to amplify a fragment of 1453 bp corresponding to 133 bp + the size of the intein inserted at the recA (a) site, ie 1320 bp.
- the demonstration of the presence of M. tubercul osi s in a sample can therefore be done using primers specific to the recA (a) insertion site of the RecA intein of this ycobacterium.
- Example 2 Specific detection of M. tuberculosis by the function of the intein inserted into the ppsl (b) site of the Ppsl protein gene.
- a particular embodiment of the invention consists in detecting Mycobacterium tuberculosis by means of the intein inserted into the ppsl (b) site of the Ppsl protein gene.
- the intein gene is amplified by PCR on the genomic DNA of M. tubercul osi s using a set of primers allowing this gene to be placed under the control of the transcription promoter of the. Phage T7 RNA polymerase, a ribosome binding site and an ATG.
- the reverse primer has one or two STOP codons.
- a negative control is produced by carrying out the same PCR on the genomic DNA of a microorganism other than M. tuberculosis.
- Example 3 Detection of a specific Mycobacterium tuberculosis intein using the detection of the endonuclease activity of the Pps1 intein, the corresponding gene of which is inserted specifically at the ppsl (b) site.
- the intein gene is amplified by PCR from genomic DNA with the following primers:
- MtuPpsl-ATG 5 'atgtgcctgcccgccggc 3' and MtuPpsl-3'SS: 5 'gttgtgcacggcgaacccgt 3'
- Genomic DNA is incubated in the presence of 10 pmol of each primer and of Taq DNA polymerase in 10 mM Tris-HCl buffer pH 8.3, 1.5 mM MgCl 2, 50 mM KCl, 0.2 mM dNTP.
- the amplification cycle is: 10 min at 92 ° C + 29 cycles (1 min. At 92 ° C + 1 min. At 55 ° C + 1.5 min at 72 ° C) + 5 min. at 72 ° C to finish.
- the 1077 bp fragment corresponding to the intein gene is purified on 1% TBE gel using the Qiaquick gel extraction kit (Qiagen) and then inserted into the expression vector pCR-T7-CT-topo according to the recommendations of the supplier (Invitrogen ).
- BL21-DE3-pLysS bacteria are transformed with a few ng of the expression plasmid and selected on LB medium containing ampicillin and chloramphenicol.
- a clone is taken up in the same medium and cultured until the exponential growth phase at 37 ° C. before induction of the expression of the intein at IPTG (1 mM). This induction at 37 ° C lasts 2 h 30 min, the cells are then centrifuged and the proteins extracted in 20 mM sodium phosphate buffer by 6 freeze-thaw cycles.
- the protein extract is then recovered by centrifugation of the cellular debris.
- the substrate plasmid is linearized by the enzyme Seal and diluted to the concentration of 100 ng / ⁇ l.
- Two independent substrate preparations are used ( Figure 2).
- Example 4 Diagnosis by PCR of Mycobacteri um tuberculosis by the simultaneous detection of two specific inteins: the ppsl intein and the recA intein.
- the ppsl intein gene is amplified by PCR from genomic DNA from M. gadium and M. tuberculosis with the following primers: ppsl-3 ': 5' gtcgttgttcgaccagttctggatggt 3 'ppsl-5': 5 'catccgcaacacctacgaccgg 3 '
- Genomic DNA of M. gadi um and M. tuberculosis are incubated in the presence of 10 pmol of each primer and of a unit of Taq DNA polymerase in 10 mM Tris-HCl buffer pH 8.3, 1.5 mM MgCl 2 , KC1 50 mM, 0.2 mM dNTP.
- the amplification cycle is: 10 min at 92 ° C + 29 cycles (1 min. At 92 ° C + 1 min. At 50 ° C + 1.5 min at 72 ° C) + 5 min. at 72 ° C to finish.
- the recA intein gene is amplified by PCR from genomic DNA of M. l eprea and M. tuberculosis with the following primers:
- the amplification products were deposited on agarose gel. After migration and coloring with BET, the results presented in FIG. 3 were observed.
- Detection of the ppsl and recA inteins of Mycoba c t eri um t ubercul osi s increases the specificity of detection.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0002051A FR2805280B1 (fr) | 2000-02-17 | 2000-02-17 | Methode de detection d'une inteine specifique de mycobacterium tuberculosis et son utilisation pour le diagnostic de la tuberculose |
FR0002051 | 2000-02-17 | ||
PCT/FR2001/000475 WO2001061035A1 (fr) | 2000-02-17 | 2001-02-16 | Methode de detection d'une inteine specifique de mycobacterium tuberculosis et son utilisation pour le diagnostic de la tuberculose |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1257666A1 true EP1257666A1 (de) | 2002-11-20 |
Family
ID=8847151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01907833A Withdrawn EP1257666A1 (de) | 2000-02-17 | 2001-02-16 | Methode zum nachweis mycobacterium tuberculosis spezifischer inteine und deren verwendung für tuberkulose |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040137511A1 (de) |
EP (1) | EP1257666A1 (de) |
AU (1) | AU2001235709A1 (de) |
FR (1) | FR2805280B1 (de) |
WO (1) | WO2001061035A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005056821A1 (en) * | 2003-12-11 | 2005-06-23 | Otago Innovation Limited | Detection of cryptococcus in a sample by detecting a mini-intein encoding region of the prp8 gene |
WO2006079057A2 (en) * | 2005-01-24 | 2006-07-27 | Boston Biomedical Research Institute | Methods and compositions for specific inhibition of protein splicing by small molecules |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731150A (en) * | 1995-11-01 | 1998-03-24 | Chiron Diagnostic Corporation | IS6110 based molecular detection of mycobacterium tuberculosis |
US5795731A (en) * | 1996-08-26 | 1998-08-18 | Health Research Incorporated | Inteins as antimicrobial targets: genetic screens for intein function |
FR2786787B1 (fr) * | 1998-12-08 | 2002-04-19 | Proteus | Methode d'analyse in vitro d'un phenotype connu a partir d'un echantillon d'acides nucleiques |
-
2000
- 2000-02-17 FR FR0002051A patent/FR2805280B1/fr not_active Expired - Fee Related
-
2001
- 2001-02-16 US US10/203,927 patent/US20040137511A1/en not_active Abandoned
- 2001-02-16 WO PCT/FR2001/000475 patent/WO2001061035A1/fr not_active Application Discontinuation
- 2001-02-16 AU AU2001235709A patent/AU2001235709A1/en not_active Abandoned
- 2001-02-16 EP EP01907833A patent/EP1257666A1/de not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0161035A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001061035A1 (fr) | 2001-08-23 |
US20040137511A1 (en) | 2004-07-15 |
AU2001235709A1 (en) | 2001-08-27 |
FR2805280B1 (fr) | 2005-01-14 |
FR2805280A1 (fr) | 2001-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2430188T5 (en) | METHOD AND KIT FOR DETECTING ANTIBIOTIC RESISTANT BACTERIA | |
EP1845158B1 (de) | Verfahren zur quantitativen analyse eines mikroorganismus mit rrna als ziel | |
JP2022520663A (ja) | in situハイブリダイゼーションによって、核酸をマルチプレックス検出する方法 | |
JP7334964B2 (ja) | Ilv3を使用した微生物の検出及び設計 | |
EP1458894A2 (de) | Verfahren zum nachweis und/oder zur identifizierung der tierart von einem in einer probe enhaltenen tierischen produkts | |
WO1998018958A1 (fr) | Procede de mise en evidence de contaminants microbiologiques vivants dans un echantillon de produit a usage alimentaire | |
US20090136930A1 (en) | Method for the identification of microorganisms by means of in situ hybridization and flow cytometry | |
EP1257666A1 (de) | Methode zum nachweis mycobacterium tuberculosis spezifischer inteine und deren verwendung für tuberkulose | |
JP3525259B2 (ja) | ペクチネータス属菌の検出 | |
FR2733755A1 (fr) | Fragment nucleotidique de l'arn ribosomique 16s de corynebacteries, sondes et amorces derivees, reactif et procede de detection | |
FR2844522A1 (fr) | Procede et sequences nucleotidiques pour la detection et l'identification de microorganismes dans un melange complexe | |
EP1137801B1 (de) | Diagnostische methode basierend auf der function eines proteins das in einer zellfreien umgebung produziert wird, ausgehend von einer probe von nukleinsäuren | |
EP1104489B1 (de) | Verfahren zur isolierung und charakterisierung potentieller funktionen ausgehend von einer biologischen probe, welche nukleinsäuren enthält | |
CN110643724A (zh) | Raa荧光法检测ndm的引物、探针、试剂盒和检测方法 | |
EP1137804B9 (de) | Kennzeichnung einer substanz mittels eines reportergens und sequenzen, die für die in vitro expression des reportergens notwendig sind | |
AU2003226729A1 (en) | Method for the identification of microorganisms by means of in situ hybridization and flow cytometry | |
KR20200048082A (ko) | 쯔쯔가무시균 감염 질환 진단용 키트 | |
JP2005006556A (ja) | ビール有害菌の検出方法 | |
CN104032000A (zh) | 蜡样芽孢杆菌的检测方法及试剂盒 | |
JP2010004880A (ja) | ビソクラミス属に属する菌類の検出方法 | |
FR2844523A1 (fr) | Procede et sequences nucleotidiques pour la detection et l'identification de microorganismes dans un melange complexe ou dans de l'eau | |
CN113512609A (zh) | 新型冠状病毒实时荧光核酸恒温扩增检测试剂盒及其专用引物和探针 | |
FR2908785A1 (fr) | Methodes de detection de microorganismes par pcr | |
KR20110002277A (ko) | 우점종 제거 기술에 기반한 희소 미생물 또는 신규 미생물의 단일 세포 유래 게놈 라이브러리의 제조방법 | |
SUNDARI et al. | Methods to Study Diversity in Soil Metagenome and Its Significance for Sustainable Soil Management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020913 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20070604 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071215 |